Niraparib metabolite M1 is primarily studied in the context of cancer treatment, particularly in relation to its parent compound, niraparib, which is a PARP inhibitor. Its applications are largely centered around understanding the pharmacokinetics and pharmacodynamics of niraparib, as it plays a role in how the drug is metabolized and excreted in the body. Researchers analyze this metabolite to assess its contribution to the overall efficacy and safety profile of niraparib in patients, especially those with ovarian cancer, breast cancer, and other malignancies where PARP inhibition is beneficial. Additionally, studying this metabolite helps in identifying potential drug-drug interactions and optimizing dosing regimens to minimize adverse effects while maintaining therapeutic effectiveness.